Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12…
Toyota Tsusho and Tokai Corp Partner to Launch Valabhi Hospital Services, Revolutionizing Hospital Linen Management in India
Toyota Tsusho Corporation, a globally recognized trading company within the Toyota Group, and Tokai Corp, a specialist in hospital linen supply and medical peripheral businesses in Japan, have joined forces to launch Valabhi Hospital Services in India. The aim of…
